Regional analysis and stage-specific incidence of breast cancer in Kazakhstan: A comprehensive study

Clinical Epidemiology and Global Health, 2024

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.1016/j.cegh.2024.101837
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background Breast cancer is the most prevalent oncological pathology in Kazakhstan, ranking among the top three causes of cancer-related deaths in women. The objective of this study is to analyze the incidence of breast cancer, considering factors such as stage, age, sex, and morphological verification in the regional context in Kazakhstan. Methods The retrospective study employed descriptive and analytical oncoepidemiological methods. Breast cancer incidence data (2005-2019) were obtained from the Unified Nationwide Electronic Health System (ICD-10 code C50). Demographic data came from the Bureau of National Statistics. Statistical analyses included age-standardized, crude, and age-specific incidence rates, with trend analyses performed using linear regression and the Joinpoint Regression Program to assess average percentage change over time. Results The analysis of breast cancer incidence in Kazakhstan shows significant regional variations and an overall upward trend. Nationally, the age-standardized incidence rate is 40.9 per 100,000, with an annual increase of +1.96%. Early-stage (I-II) breast cancer incidence is rising, particularly in Pavlodar, North Kazakhstan, and Almaty City. In contrast, advanced-stage (III-IV) incidence has generally declined, except in regions like Kostanay, North Kazakhstan, and Atyrau, where late-stage cases are increasing. High morphological verification rates across all regions ensure reliable and accurate diagnostic data. Conclusion The study reveals a significant increase in early-stage breast cancer diagnoses in Kazakhstan, highlighting the effectiveness of the national screening program. However, regional disparities in late-stage cancer incidence suggest a need for targeted interventions and improved regional healthcare.